Chk
Los inhibidores de la quinasa de control de ciclo (Chk) se dirigen a las quinasas Chk1 y Chk2, que son reguladores clave de la respuesta al daño del ADN y los puntos de control del ciclo celular. Estas quinasas detienen la progresión del ciclo celular en respuesta al daño en el ADN, permitiendo tiempo para la reparación. Inhibir las quinasas Chk puede evitar el arresto del ciclo celular, forzando a las células dañadas a continuar con el ciclo y, finalmente, someterse a apoptosis. Los inhibidores de Chk son particularmente valiosos en la investigación del cáncer, donde pueden sensibilizar las células tumorales a los agentes que dañan el ADN. En CymitQuimica, ofrecemos una variedad de inhibidores de Chk de alta calidad para apoyar su investigación en la respuesta al daño del ADN, la regulación del ciclo celular y la oncología.
Se han encontrado 42 productos de "Chk"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Monalizumab
CAS:<p>Monalizumab, a humanized antibody, enhances NK cell function by inhibiting NKG2A; used in HNSCC studies.</p>Pureza:95% - > 95%Forma y color:LiquidPeso molecular:147 kDa (average)CHK1-IN-4 hydrochloride
<p>CHK1-IN-4 hydrochloride is a potent inhibitor of checkpoint kinase 1 (chk1).</p>Fórmula:C18H19BrClN7O2Pureza:99.29%Forma y color:SoildPeso molecular:480.75Zimistobart
CAS:<p>Zimistobart (BMS-986315) is a fully human IgG1 antibody that targets and binds to NKG2A. It is applicable in research for non-small cell lung cancer (NSCLC). For an isotype control, refer to HumanIgG1kappa, Isotype Control.</p>Forma y color:LiquidWAY-230563
CAS:<p>WAY-230563 is a serine/threonine kinase inhibitor that blocks CHK1/CHK2-mediated cell cycle checkpoints, leading to G2/M phase arrest in tumour cells</p>Fórmula:C17H12N2O2SPureza:98.40%Forma y color:SolidPeso molecular:308.35CBP501 Affinity Peptide
CAS:<p>CBP501 Affinity Peptide, a Chk kinase inhibitor, disrupts G2 arrest triggered by DNA-damaging agents and is utilized in cancer research [1].</p>Fórmula:C68H119N21O25SForma y color:SolidPeso molecular:1662.86Chk1-IN-6
CAS:<p>Chk1-IN-6 is a potent, selective, and orally bioavailable CHK1 inhibitor candidate.</p>Fórmula:C16H18F3N7Forma y color:SolidPeso molecular:365.364CCT241533 dihydrochloride
CAS:<p>Potent Chk2 inhibitor with 3 nM IC50, 63-fold more selective over Chk1, affects 84 kinases, reduces DNA damage response and apoptosis in cells.</p>Fórmula:C23H29Cl2FN4O4Forma y color:SolidPeso molecular:515.41CHK1-IN-12
<p>CHK1-IN-12 (Compound example 1-5) is a highly selective and orally active checkpoint kinase 1 (CHK1) inhibitor, demonstrating an in vitro enzyme IC50 of ≤10 nM and a cellular IC50 of ≤50 nM. This compound suppresses the phosphorylation activity of CHK1 kinase, disrupts DNA damage response pathways, and induces tumor cell cycle arrest and apoptosis. CHK1-IN-12 shows promise for cancer research applications.</p>Fórmula:C19H19N7O2Forma y color:SolidPeso molecular:377.16002CHK1-IN-9
<p>CHK1-IN-9 (compound 11) is an orally active CHK1 inhibitor with an IC50 of 0.55 nM. It enhances the effects of DNA-damaging agents on tumor cells and exhibits synergistic anticancer activity with Gemcitabine.</p>GDC-0425
CAS:<p>GDC-0425 (RG-7602), an oral selective ChK1 inhibitor, targets multiple cancers.</p>Fórmula:C18H19N5OForma y color:SolidPeso molecular:321.38GDC-0575 dihydrochloride
CAS:<p>GDC-0575 dihydrochloride (ARRY-575 dihydrochloride) is a selective, orally active CHK1 inhibitor (IC50: 1.2 nM) that exhibits antitumour effects.</p>Fórmula:C16H22BrCl2N5OForma y color:SolidPeso molecular:451.19CCT244747
CAS:<p>CCT244747 is a potent and selective CHK1 inhibitor oral, ATP-competitive, and cytotoxic, abrogating drug-induced S and G2 blockade and inducing apoptosis .</p>Fórmula:C20H24N8O2Pureza:99.17%Forma y color:SolidPeso molecular:408.46GDC0575 monohydrochloride
CAS:<p>GDC0575 (ARRY575), a potent Chk1 inhibitor, IC50 1.2nM, disrupts cell cycle arrest, allowing DNA repair before mitosis.</p>Fórmula:C16H21BrClN5OPureza:97.85%Forma y color:SolidPeso molecular:414.73GDC-0575
CAS:<p>GDC-0575 (ARRY-575) is a highly-selective oral small-molecule Chk1 inhibitor(IC50 of 1.2 nM).</p>Fórmula:C16H20BrN5OPureza:≥95%Forma y color:SolidPeso molecular:378.27SAR-020106
CAS:<p>SAR-020106 is a potent, ATP-competitive, and selective CHK1 inhibitor with an IC50 of 13.3 nmol/L on the isolated human enzyme.</p>Fórmula:C19H19ClN6OPureza:97.78%Forma y color:SolidPeso molecular:382.85LY2880070
CAS:<p>LY2880070 is a new checkpoint kinase 1 (CHK1) inhibitor for cancer therapy.</p>Fórmula:C19H23N7O2Pureza:99.77%Forma y color:SolidPeso molecular:381.43CCT245737
CAS:<p>CCT245737 is an orally active, selective Chk1 inhibitor, and is >1,000-fold selective over CHK2 and CDK1.Cost-effective and quality-assured.</p>Fórmula:C16H16F3N7OPureza:98.06% - 99.69%Forma y color:SolidPeso molecular:379.34SCH900776
CAS:<p>SCH900776 (MK-8776) is an agent targeting cell cycle checkpoint kinase 1 (Chk1) with potential radiosensitization and chemosensitization activities.</p>Fórmula:C15H18BrN7Pureza:96.69% - 99.6%Forma y color:SolidPeso molecular:376.25Rabusertib
CAS:<p>Rabusertib (IC-83) is a chk1 inhibitor in trials for various cancers, including pancreatic and non-small cell lung cancer.</p>Fórmula:C18H22BrN5O3Pureza:98.86% - 99.87%Forma y color:SolidPeso molecular:436.3AZD-7762
CAS:<p>AZD-7762, an effective and specific inhibitor of Chk1（IC50=5 nM）, is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck.</p>Fórmula:C17H19FN4O2SPureza:98.96% - 99.19%Forma y color:SolidPeso molecular:362.42
